Morgan Stanley’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $27.1M | Buy |
7,253,469
+143,364
| +2% | +$535K | ﹤0.01% | 2509 |
|
|
2025
Q1 | $19.6M | Buy |
7,110,105
+3,762,298
| +112% | +$10.4M | ﹤0.01% | 2713 |
|
|
2024
Q4 | $18.5M | Buy |
3,347,807
+2,564,875
| +328% | +$14.2M | ﹤0.01% | 2823 |
|
|
2024
Q3 | $6.53M | Buy |
782,932
+449,314
| +135% | +$3.75M | ﹤0.01% | 3750 |
|
|
2024
Q2 | $2.27M | Sell |
333,618
-253,175
| -43% | -$1.72M | ﹤0.01% | 4479 |
|
|
2024
Q1 | $3.85M | Sell |
586,793
-2,862,619
| -83% | -$18.8M | ﹤0.01% | 4121 |
|
|
2023
Q4 | $22.4M | Buy |
3,449,412
+2,451,652
| +246% | +$15.9M | ﹤0.01% | 3231 |
|
|
2023
Q3 | $5.02M | Buy |
997,760
+858,170
| +615% | +$4.32M | ﹤0.01% | 3736 |
|
|
2023
Q2 | $1.22M | Sell |
139,590
-2,346
| -2% | -$20.5K | ﹤0.01% | 4716 |
|
|
2023
Q1 | $1.68M | Buy |
141,936
+123,878
| +686% | +$1.47M | ﹤0.01% | 4563 |
|
|
2022
Q4 | $184K | Buy |
18,058
+10,815
| +149% | +$110K | ﹤0.01% | 5699 |
|
|
2022
Q3 | $42K | Sell |
7,243
-11,428
| -61% | -$66.3K | ﹤0.01% | 6483 |
|
|
2022
Q2 | $46K | Buy |
18,671
+10,180
| +120% | +$25.1K | ﹤0.01% | 6652 |
|
|
2022
Q1 | $25K | Sell |
8,491
-80,965
| -91% | -$238K | ﹤0.01% | 7049 |
|
|
2021
Q4 | $632K | Buy |
89,456
+63,412
| +243% | +$448K | ﹤0.01% | 5402 |
|
|
2021
Q3 | $271K | Sell |
26,044
-787
| -3% | -$8.19K | ﹤0.01% | 5838 |
|
|
2021
Q2 | $329K | Buy |
+26,831
| New | +$329K | ﹤0.01% | 5757 |
|